1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
672C96B388478178D88256B66005D5EC8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/prioritizing-ma-opportunities-to-ensure-growth-and-value-part-2?opendocument
18
19opendocument
2035.175.191.36
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Mergers and Acquisitions

Prioritizing M&A Opportunities to Ensure Growth and Value -- Part 2

DB Image

ID: 2880


Features:

Graphics


Words: 1,246


Published: Pre-2016


Delivery Format: Online


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
This document discusses the following practices: Conducting systematic portfolio reviews to identify high-value assets and minimize redundant assets when prioritizing M&A opportunities. Employing a collaborative approach to capture all growth and value elements when planning and prioritizing M&A combinations.

Industries Profiled:
Computers; Manufacturing; Pharmaceutical; Health Care; Diagnostic; Computer Software


Companies Profiled:
GlaxoSmithKline; Sanofi-aventis; Burroughs Wellcome; ABB; AstraZeneca; Synopsys

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.